(Q36036173)

English

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

8

object named as

Ann S LaCasce

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Andrew A Lane

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Philippe Armand

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yang Feng

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Donna S Neuberg

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jeremy S Abramson

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jennifer R Brown

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

David C Fisher

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Eric D Jacobsen

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Steven L McAfee

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Thomas R Spitzer

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Arnold S Freedman

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yi-Bin Chen

13

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

3 January 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

53

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1130-1136

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Anthracycline cardiotoxicity: from bench to bedside

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

2 October 2017

Comparative study on the influence of two 2-chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione-related enzymes in different organs of the rat.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

11 July 2018

Pulmonary Toxicity Associated with Bischloroethylnitrosourea (BCNU)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

11 July 2018

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

23 September 2018

Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

23 September 2018

Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

23 September 2018

High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of p

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376378

23 September 2018

Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.645208

21 January 2018

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.645208

21 January 2018

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22132836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22132836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22132836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22132836

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2011.645208

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

release_asdojcemdzezlj2uy2vpegnxbu

1 reference

https://api.fatcat.wiki/v0/release/asdojcemdzezlj2uy2vpegnxbu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36036173&oldid=1984561550"